Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29.
In this photo illustration, the Lantheus Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
In this photo illustration, the Lantheus Holdings logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)
Profile Image
Anan Ashraf·Stocktwits
Published Mar 17, 2026   |   4:49 PM EDT
Share
·
Add us onAdd us on Google

Lantheus Holdings, Inc. said on Tuesday that the U.S. Food and Drug Administration has extended its review of LNTH-2501 by three months.

The agency is now slated to decide on the company’s application seeking approval for the diagnostic kit by June 29. The extended deadline is expected to give the agency additional time to review and consider further manufacturing related information submitted by Lantheus, it said.

The extension, however, is not related to the efficacy or safety data of LNTH-2501, a radioactive diagnostic kit for detecting somatostatin receptor positive neuroendocrine tumors in adults as well as pediatric patients, the company added. 

Get updates to this developing story directly on Stocktwits.

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy